Announcements Trials
Browse Landscape

Phase

Phase 1/2 9Phase 1 5Phase 2 4Phase EARLY_PHASE1 1Phase 3 1Phase 2/3 1

Status

Withdrawn 1Unknown 1Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 3OTHER 2

Study Type

Interventional 5

Sponsor

Cancer Type

Lymphoid 4Other hematologic neoplasm 3CNS 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Waldenstrom Macroglobulinemia 1Recurrence 1Neuroblastoma 1Lymphoma, Non-Hodgkin 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1

Interventions

Cyclophosphamide 624pembrolizumab 500Paclitaxel 456Gemcitabine 438Carboplatin 435Cisplatin 418Radiotherapy 380fludarabine 365Nivolumab 340Docetaxel 277Bevacizumab 276Irinotecan 257Magnetic Resonance Spectroscopy 242Fluorouracil 228Dexamethasone 225Specimen Handling 221Capecitabine 218Rituximab 205Cytarabine 201Oxaliplatin 200Ipilimumab 199Temozolomide 197Biopsy 196fludarabine phosphate 194Etoposide 181Lenalidomide 176Doxorubicin 175Leucovorin 173Cetuximab 171Injections 170

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 1 × Lisaftoclax × Clear all
NCT07428486 2026-05-07

A Phase 1 Study Of FLAG Chemotherapy In Combination With Lisaftoclax And Pelcitoclax In Patients With Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia

M.D. Anderson Cancer Center

Phase 1 Withdrawn
LymphoidOther hematologic neoplasm

Recurrence, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03913949 2026-05-01

A Study to Evaluate the Safety,PK and PD of APG-2575 in Patients With Hematologic Malignancies

Ascentage Pharma Group Inc.

Phase 1 Active not recruiting
74 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell

NCT04260217 2025-08-19

MAPLE-1

Ascentage Pharma Group Inc.

Phase 1 Completed
46 enrolled
Lymphoid

Waldenstrom Macroglobulinemia

NCT05701306 2025-02-25

APG-115 Alone or in Combination With APG-2575 in Children With Recurrent or Refractory Neuroblastoma or Solid Tumors

Ascentage Pharma Group Inc.

Phase 1 Recruiting
100 enrolled
CNS

Neuroblastoma

NCT05495035 2023-03-02

Study for Safety and Efficacy of Olverembatinib Combined With APG-2575 in Children With Relapsed/Refractory Ph + ALL

Institute of Hematology & Blood Diseases Hospital, China

Phase 1 Unknown
22 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡